These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16345016)

  • 1. Rater bias in a blinded randomized placebo-controlled psychiatry trial.
    Marcus SM; Gorman JM; Tu X; Gibbons RD; Barlow DH; Woods SW; Katharine Shear M
    Stat Med; 2006 Aug; 25(16):2762-70. PubMed ID: 16345016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine.
    Ninan PT
    J Clin Psychiatry; 1997; 58 Suppl 5():24-31. PubMed ID: 9184624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-trial evaluation of the potential for unblinding in drug trials: a prototype example.
    Walter SD; Awasthi S; Jeyaseelan L
    Contemp Clin Trials; 2005 Aug; 26(4):459-68. PubMed ID: 16054578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in beliefs identify unblinding in randomized controlled trials: a method to meet CONSORT guidelines.
    Rees JR; Wade TJ; Levy DA; Colford JM; Hilton JF
    Contemp Clin Trials; 2005 Feb; 26(1):25-37. PubMed ID: 15837450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies should be controlled, randomized, and blinded.
    Parker RA
    Clin Pharmacol Ther; 2009 May; 85(5):461-3. PubMed ID: 19381148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders.
    Pull CB
    Curr Opin Psychiatry; 2007 Jan; 20(1):30-5. PubMed ID: 17143079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven criteria for improving effectiveness trials in psychiatry.
    Tansella M; Thornicroft G; Barbui C; Cipriani A; Saraceno B
    Psychol Med; 2006 May; 36(5):711-20. PubMed ID: 16512969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical analysis of possible bias of clinical judgements due to observing an on-therapy marker variable.
    Boateng F; Sampson A; Schwab B
    Stat Med; 1996 Aug; 15(16):1747-55. PubMed ID: 8870157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychotherapy in psychiatry.
    Gabbard GO
    Int Rev Psychiatry; 2007 Feb; 19(1):5-12. PubMed ID: 17365154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the issue of channeling bias in observational studies with propensity scores analysis.
    Lobo FS; Wagner S; Gross CR; Schommer JC
    Res Social Adm Pharm; 2006 Mar; 2(1):143-51. PubMed ID: 17138506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eliminating bias in randomized controlled trials: importance of allocation concealment and masking.
    Viera AJ; Bangdiwala SI
    Fam Med; 2007 Feb; 39(2):132-7. PubMed ID: 17273956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing exposure of clinical research subjects to placebo treatments.
    Noble RE; Gelfand LA; DeRubeis RJ
    J Clin Psychol; 2005 Jul; 61(7):881-92. PubMed ID: 15827998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinded assessment of treatment effects utilizing information about the randomization block length.
    Miller F; Friede T; Kieser M
    Stat Med; 2009 May; 28(12):1690-706. PubMed ID: 19340815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity analysis for m-estimates, tests, and confidence intervals in matched observational studies.
    Rosenbaum PR
    Biometrics; 2007 Jun; 63(2):456-64. PubMed ID: 17688498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudo cluster randomization: a treatment allocation method to minimize contamination and selection bias.
    Borm GF; Melis RJ; Teerenstra S; Peer PG
    Stat Med; 2005 Dec; 24(23):3535-47. PubMed ID: 16007575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial.
    Piaggio G; Elbourne D; Schulz KF; Villar J; Pinol AP; Gülmezoglu AM;
    BMC Med Res Methodol; 2003 Oct; 3():19. PubMed ID: 14525622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity designs for preventing bias replication in randomized clinical trials.
    Berger VW; Grant WC; Vazquez LF
    Stat Methods Med Res; 2010 Aug; 19(4):415-24. PubMed ID: 20488837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model misspecification sensitivity analysis in estimating causal effects of interventions with non-compliance.
    Jo B
    Stat Med; 2002 Nov; 21(21):3161-81. PubMed ID: 12375297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trussed in evidence? Ambiguities at the interface between clinical evidence and clinical practice.
    Healy D
    Transcult Psychiatry; 2009 Mar; 46(1):16-37. PubMed ID: 19293278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.